These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38421659)

  • 1. GLP-1 Agonists for Obesity-A New Recipe for Success?
    Mozaffarian D
    JAMA; 2024 Mar; 331(12):1007-1008. PubMed ID: 38421659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    Emanuel EJ; Dellgren JL; McCoy MS; Persad G
    N Engl J Med; 2024 May; 390(20):1839-1842. PubMed ID: 38630999
    [No Abstract]   [Full Text] [Related]  

  • 3. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
    George C; Byun A; Howard-Thompson A
    Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits MM; Holst JJ
    Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.
    Režić T; Blaslov K; Kruljac I; Rahelić D; Vrkljan M; Renar IP
    Med Hypotheses; 2019 Oct; 131():109308. PubMed ID: 31443779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
    Conlon JM; O'Harte FPM; Flatt PR
    Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
    Lehmann EW; Torekov SS
    Cardiovasc Res; 2021 Aug; 117(10):e120-e122. PubMed ID: 34448813
    [No Abstract]   [Full Text] [Related]  

  • 13. Obesity and GLP-1 RAs.
    Bright T
    J Investig Med; 2022 Jan; 70(1):1-2. PubMed ID: 34949727
    [No Abstract]   [Full Text] [Related]  

  • 14. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer GLP-1 receptor agonists and obesity-diabetes.
    Brown E; Cuthbertson DJ; Wilding JP
    Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin therapy for diabetes mellitus type 2.
    Holst JJ
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):2-10. PubMed ID: 31815785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
    Spezani R; Mandarim-de-Lacerda CA
    Life Sci; 2022 Jan; 288():120188. PubMed ID: 34861287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-obesity drugs : from previous disappointments to new hopes].
    Scheen A; De Flines J; Paquot N
    Rev Med Liege; 2023 Mar; 78(3):147-152. PubMed ID: 36924152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.